A detailed history of Nuveen Asset Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 455,313 shares of RVNC stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
455,313
Previous 1,056,062 56.89%
Holding current value
$1.17 Million
Previous $2.71 Million 56.89%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.57 - $2.57 $1.54 Million - $1.54 Million
-600,749 Reduced 56.89%
455,313 $1.17 Million
Q2 2024

Aug 09, 2024

BUY
$2.34 - $4.73 $1.65 Million - $3.33 Million
704,020 Added 199.98%
1,056,062 $2.71 Million
Q1 2024

May 13, 2024

SELL
$4.65 - $9.31 $842,366 - $1.69 Million
-181,154 Reduced 33.98%
352,042 $1.73 Million
Q4 2023

Feb 14, 2024

SELL
$5.81 - $11.2 $408,448 - $787,371
-70,301 Reduced 11.65%
533,196 $4.69 Million
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $2.31 Million - $5.04 Million
201,103 Added 49.98%
603,497 $6.92 Million
Q2 2023

Aug 14, 2023

BUY
$24.7 - $37.61 $2,766 - $4,212
112 Added 0.03%
402,394 $10.2 Million
Q1 2023

May 15, 2023

SELL
$18.36 - $35.27 $1.81 Million - $3.48 Million
-98,565 Reduced 19.68%
402,282 $13 Million
Q4 2022

Feb 14, 2023

SELL
$18.32 - $30.66 $2.17 Million - $3.63 Million
-118,317 Reduced 19.11%
500,847 $9.25 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $3.73 Million - $7.4 Million
260,044 Added 72.41%
619,164 $16.7 Million
Q2 2022

Aug 15, 2022

SELL
$11.52 - $20.4 $134,795 - $238,700
-11,701 Reduced 3.16%
359,120 $4.96 Million
Q1 2022

May 16, 2022

SELL
$12.36 - $20.31 $35,979 - $59,122
-2,911 Reduced 0.78%
370,821 $7.07 Million
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $136,212 - $304,674
-10,932 Reduced 2.84%
373,732 $6.1 Million
Q3 2021

Nov 12, 2021

SELL
$25.78 - $33.21 $4.55 Million - $5.86 Million
-176,430 Reduced 31.44%
384,664 $10.7 Million
Q2 2021

Aug 16, 2021

BUY
$26.8 - $31.84 $2.81 Million - $3.34 Million
104,771 Added 22.96%
561,094 $16.6 Million
Q1 2021

May 17, 2021

SELL
$24.03 - $29.97 $476,418 - $594,185
-19,826 Reduced 4.16%
456,323 $12.8 Million
Q4 2020

May 17, 2021

SELL
$23.41 - $28.34 $334,084 - $404,440
-14,271 Reduced 2.91%
476,149 $13.5 Million
Q4 2020

Feb 16, 2021

BUY
$23.41 - $28.34 $1.51 Million - $1.83 Million
64,399 Added 15.12%
490,420 $13.9 Million
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $584,582 - $863,159
25,165 Added 6.28%
426,021 $10.7 Million
Q2 2020

Aug 14, 2020

BUY
$12.6 - $26.55 $625,035 - $1.32 Million
49,606 Added 14.12%
400,856 $9.79 Million
Q1 2020

May 14, 2020

BUY
$12.46 - $27.81 $305,693 - $682,290
24,534 Added 7.51%
351,250 $5.2 Million
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $225,551 - $389,781
19,344 Added 6.29%
326,716 $5.3 Million
Q3 2019

Nov 14, 2019

BUY
$10.22 - $14.5 $1.06 Million - $1.51 Million
104,035 Added 51.16%
307,372 $4 Million
Q2 2019

Aug 15, 2019

BUY
$10.67 - $15.49 $2.17 Million - $3.15 Million
203,337 New
203,337 $2.64 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.